^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GS-9716

    i
    Other names: GS-9716, GS9716, GS 9716
    Associations

    News

    Trials
    Company:
    Gilead
    Drug class:
    MCL1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    11ms
    Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies (clinicaltrials.gov)
    P1, N=195, Recruiting, Gilead Sciences
    Trial completion date • Trial primary completion date • Combination therapy
    |
    docetaxel • Trodelvy (sacituzumab govitecan-hziy) • GS-9716
    over2years
    GS-9716: A potent, selective and orally bioavailable small molecule inhibitor of MCL1 for the treatment of cancer (AACR 2022)
    In addition to single agent activity, GS-9716 showed strong synergy with multiple anti-cancer therapies; robust in vitro synergy was observed with venetoclax in the AML models and as well as with paclitaxel in the TNBC models. Similar responses were also observed when GS-9716 was dosed with paclitaxel in the TNBC PDX models. GS-9716 is currently in Phase 1 clinical trial evaluating safety, tolerability and pharmacokinetics as monotherapy and in combination with anticancer therapies in adults with advanced solid tumors (NCT05006794).
    IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1)
    |
    Venclexta (venetoclax) • paclitaxel • GS-9716